Approval was supported by the phase 3 LANDI-PED study, which demonstrated significant heart rate reduction and conversion to normal sinus rhythm in pediatric patients.
The approval was based on data from 5 randomized, double-blind, placebo-controlled trials that included 317 patients with supraventricular tachycardia. Landiolol is a selective beta-1 adrenergic ...
There are several superficial vein thrombosis treatment options. A person’s symptoms and overall health can influence the type of treatment they receive. Superficial vein thrombosis (SVT), also known ...
Catheter ablation was not the first-line treatment for supraventricular tachycardia (SVT) for most patients referred to a tertiary center, a study shows, with investigators suggesting the procedure is ...
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
Please provide your email address to receive an email when new articles are posted on . Etripamil, a novel fast-acting calcium channel blocker administered via nasal spray, was not superior to placebo ...
DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...
Shares of Milestone Pharmaceuticals Inc. gained 25.4% in premarket trading on Monday after the company said its experimental treatment for paroxysmal supraventricular tachycardia met the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results